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Context: Vitamin D deficiency contributes to skeletal diseases and is highly prevalent among
institutionalized elderly patients.Whether low25-hydroxyvitaminD (25[OH]D) concentrations are
an independent risk factor for mortality in these patients is, however, unclear.
Objective:We aimed to evaluate whether 25(OH)D concentrations are associated with mortality.
Design, Setting, and Participants: This is a prospective cohort study among elderly female patients
(age 70 yr) recruited from 95 nursing homes in Austria.
MainOutcomeMeasures:WecalculatedCoxproportionalhazard ratios (HR) forall-causemortality
according to 25(OH)D quartiles.
Results:We examined 961 study participants (age 83.7 6.1 yr). Median 25(OH)D concentration was
17.5 (interquartile range 13.7–25.5) nmol/liter, and 93% of our cohort had 25(OH)D levels below 50
nmol/liter. During a mean follow-up time of 27  8 months, 284 patients died. Compared with the
fourth quartile (25[OH]D25.5 nmol/liter), the age-adjusted HR (with 95% confidence interval) was
1.49 (1.07–2.10) in the first 25(OH)Dquartile (25[OH]D14.0nmol/liter), and this association remained
significant after multivariate adjustments (HR 1.56; 95% confidence interval 1.01–2.40).
Conclusions: This Austrian study suggests that themajority of institutionalized female patients are
vitamin D deficient during winter and that there was an inverse association of 25(OH)D and
mortality. These data underscore the urgent need for effective strategies for the prevention and
treatment of vitamin D deficiency, in particular in the setting of nursing homes. (J Clin Endocrinol
Metab 97: E653–E657, 2012)
Vitamin D deficiency is considered a causal risk factorfor skeletal diseases, which justifies recommenda-
tions for dietary vitamin D intakes (1, 2). Particular at-
tention is paid to institutionalized elderly patients because
prevalence of vitamin D deficiency is extraordinarily high
among these individuals (2, 3). This in turn led to recom-
mendations for vitamin D intake doses in the elderly
(mostly 800 IU/d) that are higher than for any other age
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group (1, 4, 5). In this context, it should also be noted that
a previous meta-analysis suggests that vitamin D supple-
mentation may decrease total mortality in older individ-
uals, but this has not been specifically addressed in elderly
institutionalized patients (6). Meta-analyses of observa-
tional studies showed an inverse relationship between vi-
tamin D status and mortality (7, 8). It has been docu-
mented that low 25-hydroxyvitamin D (25[OH]D)
concentrations are associated with increased risk of mor-
tality in the general population as well as in patients with
chronic kidney disease (7, 8). By contrast, the situation is
less clear for institutionalized elderlypatients becauseonly
one previous study addressed this topic in such individuals
(9). In that study, Sambrook et al. (9) examined 842 older
people (mean age 81.9 yr; 78.4% females) residing in hos-
tels and nursing homes in Northern Sydney. Higher
25(OH)Dwas associatedwith decreasedmortality in age-
and gender-adjusted analyses, but therewas no significant
relationship aftermultivariate adjustments (9). Therefore,
the independent association of 25(OH)D with mortality
remains to be further studied.We addressed this in a large
prospective cohort of female nursing home residents in
Austria (10, 11).
Subjects and Methods
Study population
Our study population consists of older (70 yr) female pa-
tients of Caucasian origin who were recruited from 95 nursing
homes in Austria. Baseline characteristics and study procedures
have been extensively described in two previously published re-
ports (10, 11). In brief, eligible study participants had to be able
to walk a short distance independently. Main exclusion criteria
weremalignancies, hypercalcemia, advancedkidney or liver dys-
function, bilateral hip replacements, history of total gastrec-
tomy, decompensated heart failure, chronic alcoholism, known
osteomalacia, untreated thyroid disease, or chronic steroid treat-
ment (10, 11). Mobility scoring was performed as previously
published (10, 11): score 1, walking independently and outside
the institution; score 2, walking inside nursing home, majority
using a walking aid but not a wheelchair; score 3, staying in bed
less than 50% during daytime, majority requiring a wheelchair;
score 4, staying in bedmore than 50%during daytime.Wemea-
sured quadriceps knee extensor strength in kiloponds. This was
done on the nondominant side by using a validated, hand-held
isometric device (model DPPH; Industrial Scale Inc., Houston,
TX). All study participants were followed up with respect to
mortality.Written informed consentwasobtained fromall study
participants, and the study protocol was approved by the local
ethics committees.
Laboratory methods
Laboratory procedures have been previously described in de-
tail, and all laboratory parameters were simultaneously mea-
sured at a single central laboratory (10, 11). Nonfasting blood
samples were collected between 0900 and 1200 h and were im-
mediately stored at 70 C until analysis. 25(OH)D was mea-
sured in serum by RIA after extraction (Immunodiagnostic
Systems, Boldon, UK). According to manufacturers instruc-
tions, the intraassay coefficients of variation were 5.3 and
5.0% at mean 25(OH)D concentrations of 26.5 and 58.4
nmol/liter, respectively. Interassay coefficients of variation
were 8.2 and 8.1% at mean 25(OH)D concentrations of 19.6
and 56.7 nmol/liter, respectively. The detection limit of our
25(OH)D assay is 3 nmol/liter. Other assay methods have
been described elsewhere (10, 11).
Statistical analyses
According to their distribution, continuous data are either
presented as means  SD or as medians with interquartile
range. Categorical data are presented as percentages. Differ-
ences across groups are tested by ANOVA for continuous
variables and by 2 test or Fisher’s exact test for categorical
data. We calculated Cox proportional hazard ratios (HR) for
mortality according to 25(OH)D quartiles with the fourth quar-
tile as the reference.We present crudeHRaswell asHRadjusted
forage (years) (model1).Additional adjustments aredone for the
possible confounders body mass index (BMI) (kilograms per
square meter) and albumin (grams per deciliter) in model 2, and
for creatinine clearance (milliliters per minute, calculated ac-
cording to Cockcroft-Gault), glycated hemoglobin (percent), ar-
terial hypertension (yes/no), and coronary artery disease (yes/no)
in model 3. Additional adjustments were performed for param-
eters ofmineralmetabolism including serumcalcium (millimoles
per liter), serumphosphate (milligramsper deciliter), andPTH in
model 4. Finally, we additionally adjust for mobility score (1–4)
and quadriceps knee extensor strength (kiloponds) inmodel 5. A
P value0.05 was considered statistically significant. SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL) was used for statistical
analyses.
Results
From the initial cohort of 1664 study participants, 961
agreed to undergo a blood draw with subsequent mea-
surements of 25(OH)D and were thus included into the
presentwork.Therewereno significant differences in clin-
ical characteristics (i.e. age, BMI, or mobility status) be-
tween those study participants with and without blood
samplings. Blood samplings for 25(OH)D were exclu-
sively performed in February andMarch 2002. Mean age
was 83.7 6.1 yr, and median 25(OH)D concentrations
were 17.5 (13.7–25.5) nmol/liter (divide by 2.496 to con-
vert nanomoles per liter to nanograms permilliliter).Only
69 patients (7.2% of the study population) had 25(OH)D
levels of 50 nmol/liter or higher. Baseline characteristics of
the study population according to 25(OH)D quartiles are
presented in Table 1.
Werecorded284deaths (30%of the studycohort) after
a mean follow-up time of 27  8 months (range 2–34
months). Cox proportionalHR formortality according to
25(OH)Dquartiles are presented in Table 2. Age-adjusted
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HR(with 95%confidence interval) formortalitywas 1.49
(1.07–2.10) in the first compared with the fourth
25(OH)D quartile, and this association remained signifi-
cant even after multivariable adjustments (see Table 2).
Discussion
In a large cohort of institutionalized elderly women, we
have shown that lower 25(OH)D levels are highly preva-
lent in winter and are associated with increasedmortality.
The observation of extremely low 25(OH)D concen-
trations in our study participants is in line with previous
investigations among institutionalized elderly people (2,
3, 12–15). Hence, our data suggest that although the high
prevalence of vitamin D deficiency among frail elderly
people in Europe has already been known for several de-
cades, no efficient strategies have meanwhile been imple-
mented to prevent and treat vitamin D deficiency in these
individuals. Limited sunlight access in concert with im-
paired vitamin D synthesis of the aging skin as well as
nutritional deficits may likewise contribute to this high
prevalence of vitaminDdeficiency. In fact, 25(OH)D con-
centrations were below the recommended level of 50
nmol/liter in almost all (92.8%) of our study participants.
These data have implications for the interpretation of our
prospective findings because even our highest group had
median 25(OH)D levels well below the cutoff for vitamin
D deficiency. Considering a meta-analysis that docu-
mented a nonlinear relationship between 25(OH)D and
mortalitywith the lowestmortality risk at 25(OH)D levels
ranging from75–87.5 nmol/liter, it could be hypothesized
that availability of an adequate reference group with such
TABLE 2. Hazard ratios (with 95% confidence intervals) for mortality according to 25(OH)D quartiles
1st quartile 2nd quartile 3rd quartile 4th quartile
Range (nmol/liter) 14.0 14.0–17.5 17.6–25.5 25.5
Crude 1.74 (1.25–2.43) 1.41 (1.00–1.98) 1.08 (0.75–1.55) 1.00 reference
Model 1 1.49 (1.07–2.10) 1.32 (0.93–1.86) 1.03 (0.72–1.48) 1.00 reference
Model 2 1.45 (1.03–2.06) 1.25 (0.88–1.79) 1.08 (0.75–1.56) 1.00 reference
Model 3 1.57 (1.10–2.23) 1.30 (0.90–1.86) 1.16 (0.80–1.68) 1.00 reference
Model 4 1.88 (1.28–2.76) 1.49 (1.02–2.16) 1.31 (0.90–1.93) 1.00 reference
Model 5 1.56 (1.01–2.40) 1.21 (0.80–1.84) 1.32 (0.88–1.97) 1.00 reference
Model 1 was adjusted for age. Model 2 was adjusted for age, BMI, and albumin. Model 3 was adjusted for covariates of model 2 plus creatinine
clearance, glycated hemoglobin, arterial hypertension, and coronary artery disease. Model 4 was adjusted for covariates of model 3 plus serum
calcium, serum phosphate, and PTH. Model 5 was adjusted for covariates of model 4 plus knee extensor strength and mobility status.
TABLE 1. Baseline characteristics according to 25(OH)D quartiles
Variable 1st quartile 2nd quartile 3rd quartile 4th quartile P
Range (nmol/liter) 14.0 14.0–17.5 17.6–25.5 25.5
Number 241 241 241 238
Age (yr) 85.5  5.6 83.6  6.2 83.3  6.0 82.2  6.2 0.001
Height (cm) 153.0  7.7 153.7  6.7 154.2  7.1 153.6  6.8 0.311
Weight (kg) 58.8  11.4 61.3  12.9 61.8  11.8 62.2  11.5 0.002
BMI (kg/m2) 25.2  4.6 26.0  5.3 26.0  4.4 26.3  4.5 0.013
PTH (pg/ml) 88 (62–135) 71 (49–95) 60 (44–85) 45 (35–62) 0.001
25(OH)D (nmol/liter) 11.7 (10.7–12.7) 15.7 (14.7–16.7) 20.7 (19.2–22.7) 36.4 (29.2–52.7) 0.001
Serum phosphate (mg/dl) 3.6  0.8 3.8  0.7 3.8  0.7 3.9  0.7 0.001
Serum calcium (mmol/liter) 2.42  0.14 2.45  0.11 2.45  0.11 2.49  0.12 0.001
Calcium supplementation (%) 1.2 0.8 4.6 18.5 0.001
Vitamin D supplementation (%) 0.4 0 2.1 14.3 0.001
Albumin (g/dl) 3.9  0.3 3.9  0.3 4.0  0.3 4.0  0.3 0.017
Creatinine clearance (ml/min) 36.4  11.4 37.6  11.8 39.3  11.7 39.0  11.8 0.005
Knee extensor strength (kiloponds) 11.7  4.9 13.3  4.9 13.3  5.3 14.2  5.9 0.001
Mobility status (%) 0.001
1 7.0 10.6 14.3 16.4
2 7.6 7.5 6.0 3.9
3 10.1 6.6 4.6 4.4
4 0.3 0.5 0.1 0
HbA1c (%) 4.9 (4.6–5.1) 4.9 (4.7–5.3) 4.9 (4.7–5.2) 4.9 (4.6–5.2) 0.143
Arterial hypertension (%) 32.8 40.7 39.8 47.9 0.010
Coronary artery diseases (%) 31.5 31.1 24.1 25.1 0.246
Data are presented as medians with interquartile range, as means with SD, or as percentages. Differences across groups were calculated with
ANOVA with P for trend and with  2 test or Fisher’s exact test. HbA1c, Glycated hemoglobin.
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high 25(OH)D levels would have contributed tomore sig-
nificant results for our data on 25(OH)D and mortality
(8). On the other hand, not all observational studies, i.e.
the work by Cawthon et al. (16) support a significant
association of 25(OH)D and mortality. However, it is
noteworthy that in the work by Cawthon et al. (16),
25(OH)D levels in the lowest category (50 nmol/liter)
weremuchhigher comparedwithour study. Inourpresent
work, there was an increase in mortality in individuals
with lower 25(OH)D levels, but it should be acknowl-
edged that inmultivariatemodels, thiswas significantonly
when comparing the fourth quartile (i.e. 25[OH]D25.5
nmol/liter) with the first quartile (i.e. 25[OH]D 14.0
nmol/liter). In line with our findings, the only other pre-
vious study addressing this issue in institutionalized el-
derly patients also indicates that low 25(OH)D may be
associated with increased mortality (9). Adjustment for
possible confounders, however, attenuated this relation-
ship in that work by Sambrook et al. (9), which underlines
the importance of our work to shed more light into this
topic. In this context, it should also be discussed that it is
very difficult to differentiate between possible confound-
ers and parameters of the causal chain of vitamin D defi-
ciencybecause vitaminDmayhave causal implications for
numerous pathophysiological processes (17–20). For
example, mobility and muscle strength were associated
with lower 25(OH)D in our cohort, but these variables
could be partially both the cause as well as the conse-
quence of vitamin D deficiency (2, 17–20). It may also
be acknowledged that due to the previously shown non-
linear associations of 25(OH)D and mortality (8), we
analyzed categorical data of 25(OH)D in our present
study, whereas Sambrook et al. (9) presented only results
on 25(OH)D concentrations as a continuous variable.
Apart fromthis,webelieve thatour findings, togetherwith
previous data on institutionalized elderly, strongly point
to the need for immediate action to prevent and treat vi-
tamin D deficiency in these patients. Considering the high
prevalence of vitamin D deficiency, it seems reasonable to
initiate vitaminDsupplementation (at least 800 IU/d) even
without previous 25(OH)D testing in such individuals (1,
5, 14, 18). Regardless of the ongoing debate on putative
extraskeletal benefits of vitamin D (e.g. cancer or cardio-
vascular disease), it should be considered that there is only
one indication needed to treat vitamin D deficiency, and
this is, at least, the proven skeletal benefit (1–8, 17–22).
Nevertheless, observational studies like ours and inter-
ventional data on vitamin D and mortality may put addi-
tional pressure on health authorities to implement more
efficient actions to fight vitaminDdeficiency, in particular
among institutionalized elderly individuals (6–8, 21). The
present data are in general agreement with the recent In-
stitute of Medicine statement that circulating 25(OH)D
levels below 30 nmol/liter bear the risk of vitamin D de-
ficiency (1).Whereas the InstituteofMedicine report relies
on bone health, the present study provides evidence that
25(OH)D levels below the aforementioned thresholdmay
also be regarded as risk factor for all-cause mortality (1).
Our results are limited because we examined elderly
female Caucasians recruited from nursing homes in Aus-
tria. These findings may therefore not be generalizable to
other populations. Given that this was a prospective ob-
servational study, we cannot draw conclusions regarding
causality. Blood samplings in February and March may
have contributed to a particularly poor vitamin D status
due to the seasonal lowering of 25(OH)D inwinter. How-
ever, this relatively narrow time window for blood col-
lectionsmay have alsominimized the possible influence of
season on our prospective analyses. We also have to ac-
knowledge that data on cause-specific mortality as well as
on vitamin D supplementation during follow-up were not
available. Despite careful adjustments, we cannot rule out
the existence of unconsidered confounders. On the other
hand, we might have overadjusted our analyses for pa-
rameters of the causal chain.
In conclusion, our Austrian study showed that the ma-
jority of elderly institutionalized women were vitamin D
deficient in winter. We observed a significantly increased
mortality risk in those patients with the lowest 25(OH)D
levels. In view of these findings and the existing literature
onadverse effects of vitaminDdeficiency, there exists now
an urgent need for effective strategies to improve vitamin
D status in older institutionalized patients.
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